EGF is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Sigumir FDA approved?

Sigumir is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is EGF administered in research settings?

In research settings, EGF is typically administered via the topical, subcutaneous, or microneedling routes. PeptideBase does not provide dosing or administration instructions.

How is Sigumir administered in research settings?

In research settings, Sigumir is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›EGF vs Sigumir

Peptide Comparison

EGF vs Sigumir

Q: What is the difference between EGF and Sigumir?

EGF: Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Sigumir: Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Both are Skin & Cosmetic peptides.

EGF

Epidermal Growth Factor

Skin & JointNot EvaluatedResearch Only

No providers listed yet

Full EGF profile →

Sigumir

Val-Glu-Pro-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

1 providers listed

Full Sigumir profile →

Bottom line

EGF carries stronger published evidence (Cohort study, 3 key studies) than Sigumir (Review, 2); both are research compounds.

Quick Verdict

EGF

Evidence

Observational

Sigumir

Evidence

Review-level

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	EGF
Oral administration option	Sigumir
More provider options (0 vs 1)	Sigumir

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

EGF

Sigumir

Mechanism Family

Skin & Cosmetic

Half-life

—

Unknown

FDA Status

not evaluated

Admin Routes

topical, subcutaneous, microneedling

subcutaneous, oral

Availability

Research Only

Providers

None listed

1 listed

Avail. Notes

—

Russian joint peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Research Evidence

EGF

ObservationalCohort study · 3 key studies · most recent 2026

Sigumir

Review-levelReview · 2 key studies · most recent 2023

Research Citations

EGF

Review2026 · Cell Tissue Bank

Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and bioc…

Cohort2026 · Gels

Development of Antiseptic and Epidermal Growth Factor Co-Loaded Thermoresponsive Composite Hydrogel for Wound…

Cohort2009 · International Wound Journal

The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary resu…

Sigumir

Review2023 · Biomolecules

Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

About EGF

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Research Areas

skin regenerationwound healingcollagen stimulationpost-procedure recovery

About Sigumir

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Research Areas

joint tissue repairbone and cartilage supportanti-inflammatory (joint)mobility improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

EGF

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Sigumir

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

EGF

Browse directory →

Providers offering

Sigumir

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.